AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie all Other Products — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment Note
Latest, Q2 2026
1,109
Period ended Jun 30, 2026
Change on a year earlier
-0.7%
1,117 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | All Other Products — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,109 | -0.7% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,025 | -18.2% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 617 | -18.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 660 | -9.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,117 | +37.9% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,253 | +68.4% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 752 | -8.4% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 726 | -7.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 810 | +9.3% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2024 | Mar 31, 2024 | 744 | +7.7% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 821 | -17.2% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 782 | -15.5% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 741 | -26.6% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 691 | -42.9% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 992 | -17.7% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 925 | -17.2% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,009 | -17.4% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,211 | -18.0% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,205 | -61.7% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,117 | +34.7% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,221 | +106.9% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,476 | +166.9% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 3,147 | +534.5% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 829 | +93.2% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 590 | +21.4% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 553 | +447.5% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 496 | -77.0% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 429 | +1,850.0% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 486 | +465.1% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2019 | Mar 31, 2019 | 101 | -28.9% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,158 | +1,054.0% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 22 | -85.1% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 86 | -70.2% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 142 | -52.2% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 187 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 148 | – | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 289 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 297 | – | Form 10-Q (filed 2018-05-04) ↗ |
Cite this data
StockData. (2026). AbbVie All Other Products — Worldwide net revenues ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/all_other_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.